Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Journal Reprint Guidance: Industry And FDA Still At Odds Over Off-Label Information

This article was originally published in The Pink Sheet Daily

Executive Summary

PhRMA says FDA’s revised draft guidance on reprints should recognize the benefits of off-label prescribing and allow communications beyond “adequate and well-controlled” clinical studies.

Advertisement

Related Content

FDA Promises More Off-label Guidances As Part Of First Amendment Harmonization
FDA’s Regulatory Rock And Hard Place: How To Handle Draft Guidances
FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts
Rx Data Mining Opponents Will Need New Pitch After Supreme Court Strikes Down Vermont Law

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS077302

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel